checkAd

StageZero Life Sciences Announces Closing of CAD$4.2 Million Private Placement with Institutional Investors

TORONTO, ON and RICHMOND, VA / ACCESSWIRE / November 26, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and …

TORONTO, ON and RICHMOND, VA / ACCESSWIRE / November 26, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, is pleased to announce that it has closed its previously announced private placement of its common shares ("Common Shares") and warrants to purchase Common Shares ("Warrants") with institutional investors for gross proceeds of approximately CAD$4.2 million (the "Private Placement"). Pursuant to the Private Placement, the Company issued 9,375,002 Common Shares and Warrants to purchase up to an aggregate of 9,375,002 Common Shares at a purchase price of CAD$0.448 per Common Share and associated Warrant. Each Warrant entitles the holder to purchase one Common Share at an exercise price of CAD$0.56 per Common Share for a period of four years following the issuance date.

H.C. Wainwright & Co. acted as the exclusive placement agent for the Private Placement.

The net proceeds of the Private Placement will be used to accelerate the Company's Global Growth Strategy and further support the commercialization of Aristotle® and AVRT. No securities were offered or sold to Canadian residents in connection with the Private Placement.

"This financing will allow us to accelerate the promotional activities around Aristotle, AVRT and TREAT and affords us the opportunity to foster new relationships with US investors as we build upon the recent OTCQB listing" said James Howard-Tripp Chairman and CEO of StageZero Life Sciences.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities referred in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, (the "U.S. Securities Act"), or any U.S. state securities laws, and such securities may not be offered or sold within the United States or to any U.S. person absent registration under U.S. federal and state securities laws or an applicable exemption from such U.S. registration requirements. "United States" and "U.S. person" have the respective meanings ascribed to them in Regulation S under the U.S. Securities Act.

Seite 1 von 3


Nachrichtenagentur: Accesswire
27.11.2021, 00:05  |  104   |   |   

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

StageZero Life Sciences Announces Closing of CAD$4.2 Million Private Placement with Institutional Investors TORONTO, ON and RICHMOND, VA / ACCESSWIRE / November 26, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and …

Nachrichten des Autors

Titel
Titel
Titel
Titel